Morikawa A,Peereboom DM,Smith QR,et al. Clinical evidence for drug penetration of capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer[J]. J Clin Oncol,2013,31:514.
[3]
Papadimitriou CA,Sarosiek T,Pikiel J,et al. A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first-and second-line therapy for HER2 overexpressing metastatic breast cancer(MBC)[C].J Clin Oncol(Meeting Abstracts),2013,31(15_suppl):516.
[4]
Fumoleau P,Largillier R,Clippe C,et al. Multicentre,phase II study evaluating capecitabine monotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer[J]. Eur J Cancer,2004,40(4):536-542.
Strosberg JR,Fine RL,Choi J,et al. First?line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas[J]. Cancer,2011,117(2):268-275.
Vauléon E,Mesbah H,Laguerre B,et al. Usefulness of chemotherapy beyond the second line for metastatic breast cancer:a therapeutic challenge[J]. Cancer Chemotherapy and Pharmacology,2010,66(1):113-120.
[16]
Taguchi T,Nakayama T,Masuda N,et al.Study of low-dose capecitabine monotherapy for metastatic breast cancer[J]. Chemotherapy,2010,56(2):166-170.